|
gptkbp:instanceOf
|
gptkb:thiazolidinedione
gptkb:antidiabetic_drug
|
|
gptkbp:approvalYear
|
1999
|
|
gptkbp:ATCCode
|
A10BG02
|
|
gptkbp:bioavailability
|
99%
|
|
gptkbp:brand
|
Avandia
|
|
gptkbp:CASNumber
|
122320-73-4
|
|
gptkbp:contraindication
|
heart failure
hepatic impairment
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:drugClass
|
gptkb:thiazolidinedione
|
|
gptkbp:eliminationHalfLife
|
3-4 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:hasMolecularFormula
|
C18H19N3O3S
|
|
gptkbp:KEGGID
|
D00422
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
PPARγ agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
70360
CHEMBL714
77999
DB00412
|
|
gptkbp:regulates
|
restricted in some countries
|
|
gptkbp:riskFactor
|
myocardial infarction
cardiovascular events
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
edema
weight gain
bone fracture
increased risk of heart failure
|
|
gptkbp:synonym
|
BRL-49653
|
|
gptkbp:UNII
|
2SMK8G1Y0Z
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes
|
|
gptkbp:bfsParent
|
gptkb:6MBT
gptkb:CYP2C8
gptkb:thiazolidinediones
gptkb:AMPK_pathway
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rosiglitazone
|